A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA's)+ high doses of insulin. - Liraglutide & Acarbose effect on HbA1c, Wt and HRQOL in type2 Diabetes

Hywel DdA Health Borad0 个研究点目标入组 66 人开始时间: 2010年6月22日最近更新: 2019年12月16日

适应症

试验速览

暂无简介。

•Age > 18 years. Male or Female. In addition, patients should fulfil all the following criteria at the randomization visit (visit 0):
•1.Type – 2 Diabetic patients with suboptimal glycaemic control despite on high doses (1 unit/kg/day OR 100units/day) of insulin.
•2.(HbA1c = 7.5%).
•3.BMI = 29
•4.On, at least: Metformin (= 1.5G/day) + SU (Gliclazide = 240mg/day or Glimepride = 4mg/day).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Previous H/O: M.I. (in last 12months),
•Congestive Cardiac Failure (NYHA class III or IV),
•Stage II, III & IV Chronic kidney disease,
•Abnormal ALT (> 3fold at baseline).
•Hypoglycaemia unawareness OR recurrent hypos requiring 3rd party assistance.
•Uncontrolled Hypertension (BP > 180/100mmHg).
•Pregnant OR likelihood of pregnancy during the study.
•Patients currently on OR treated in the last 12-months with a glitazone, DPP-IV, GLP analogue, Acarbose, steroides.
•History of inflammatory bowel disease, previous abdominal surgery, history or presence of intestinal obstruction / Hernia.
•History of Diabetic ketoacidosis, gasteroparesis and pancreatitis.

发起方

Hywel DdA Health Borad